Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system

被引:111
|
作者
Berget, Cari [1 ]
Messer, Laurel H. [1 ]
Vigers, Tim [2 ]
Frohnert, Brigitte I. [1 ]
Pyle, Laura [1 ,2 ]
Wadwa, R. Paul [1 ]
Driscoll, Kimberly A. [1 ,3 ]
Forlenza, Gregory P. [1 ]
机构
[1] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Anschutz Campus, Aurora, CO 80045 USA
[2] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA
[3] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA
关键词
pediatrics; artificial pancreas; automated insulin delivery; continuous glucose monitor; INSULIN DELIVERY-SYSTEM; QUALITY-OF-LIFE; PROBLEM AREAS; TYPE-1; ADOLESCENTS;
D O I
10.1111/pedi.12962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system. Subjects Youth with type 1 diabetes (2-25 years) starting the 670G HCL system for their diabetes care were enrolled in an observational study. Methods Prospective data collection occurred during routine clinical care and included glycemic variables (sensor time in range [70-180 mg/dL], HbA1c), and psychosocial variables (Hypoglycemia Fear Survey [HFS]; Problem Areas in Diabetes [PAID]). Mixed models were used to analyze change across time. Results Ninety-two youth (mean age 15.7 +/- 3.6 years, 50% female, HbA1c 8.8% +/- 1.8%) started HCL for their diabetes care. Youth used Auto Mode 65.5% +/- 3.0% of the time at month 1, which decreased to 51.2% +/- 3.4% at month 6 (P = .001). Sensor time in range increased from 50.7% +/- 1.8% at baseline to 56.9% +/- 2.1% at 6 months (P = .007). HbA1c decreased from 8.7% +/- 0.2% at baseline to 8.4% +/- 0.2% after 6 months of use (P <= .0001), with the greatest HbA1c decline in participants with high baseline HbA1c. Increased percent time in auto mode was associated with lower HbA1c (P = .02). Thirty percent of youth discontinued HCL in the first 6 months of use. There were no changes in the HFS or PAID scores across time. Conclusions HCL use is associated with improved glycemic control and no change in psychosocial outcomes in this clinical sample. The decline in HCL use across time suggests that youth experience barriers in sustaining use of HCL. Further research is needed to understand reasons for HCL discontinuation and determine intervention strategies.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
  • [1] REAL-WORLD USE OF THE MINIMED™ 670G HYBRID CLOSED-LOOP SYSTEM
    Agrawal, P.
    Stone, M.
    Cordero, T.
    Lee, S.
    Shin, J.
    Kaufman, F.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A18 - A19
  • [2] REAL-WORLD ASSESSMENT OF FORMER MDI PATIENTS' EXPERIENCE ON THE MEDTRONIC MINIMED™ 670G HYBRID CLOSED-LOOP SYSTEM
    Gopalakrishnan, S.
    Mueckler, J.
    Jinghua, C.
    Jordin, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A85 - A86
  • [3] Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months
    Messer, Laurel H.
    Berget, Cari
    Vigers, Tim
    Pyle, Laura
    Geno, Cristy
    Wadwa, R. Paul
    Driscoll, Kimberly A.
    Forlenza, Gregory P.
    PEDIATRIC DIABETES, 2020, 21 (02) : 319 - 327
  • [4] Comparison of Six Months Experience on Hybrid Closed Loop MiniMed 670G System and Advanced Hybrid Closed Loop MiniMed 780G System Using a Structured Initiation Protocol in Children and Adolescents with Type 1 Diabetes
    Petrovski, Goran
    Campbell, Judith
    Alkhalaf, Fawziya
    Hussain, Khalid
    DIABETES, 2022, 71
  • [5] Real-world performance of the MiniMed™ 670G system in Europe
    Da Silva, Julien
    Bosi, Emanuele
    Jendle, Johan
    Arrieta, Arcelia
    Castaneda, Javier
    Grossman, Benyamin
    Cordero, Toni L.
    Shin, John
    Cohen, Ohad
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1942 - 1949
  • [6] Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
    Messer, Laurel H.
    Forlenza, Gregory P.
    Sherr, Jennifer L.
    Wadwa, R. Paul
    Buckingham, Bruce A.
    Weinzimer, Stuart A.
    Maahs, David M.
    Slover, Robert H.
    DIABETES CARE, 2018, 41 (04) : 789 - 796
  • [7] Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1508): : 147 - 148
  • [8] Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System
    DuBose, Stephanie N.
    Bauza, Colleen
    Verdejo, Alandra
    Beck, Roy W.
    Bergenstal, Richard M.
    Sherr, Jennifer
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (12) : 791 - 798
  • [9] Real-World Data from the MiniMed™ 670G System Commercial Launch
    Agrawal, Pratik
    Stone, Michael
    Gopalakrishnan, Shweta
    Fogel, Catherine
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES, 2018, 67
  • [10] EXPLORATORY ANALYSIS OF HYBRID CLOSED-LOOP ALGORITHM ADAPTATION DURING MINIMED™ 670G SYSTEM USE BY CHILDREN, ADOLESCENTS, AND ADULTS
    Shin, J.
    Liu, M.
    Chen, X.
    Huang, S. Huang
    Cordero, T.
    Lee, S.
    Kaufman, F.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A82 - A83